Rapid Response: How Cost Plus Drugs is revolutionizing pharma, with CEO Alex Oshmyansky

Episode Summary

Executive Summary: Alex Oshmiansky, CEO and co-founder of Cost Plus Drugs, explains how the company is disrupting the opaque U.S. drug supply chain by selling medications at transparent cost-plus pricing, bypassing pharmacy benefit managers (PBMs) that inflate prices. He traces his path from physician and researcher to founder, describes rapid growth driven by word of mouth, and details the company’s expansion into manufacturing, robotics, AI, and bulk sales to institutions.

Main Topics: Cost Plus Drugs’ transparent pricing model (Priority: 5/5): Oshmiansky explains that the company sells drugs at true cost plus small fixed fees, aiming to expose and undercut hidden markups in the pharmaceutical supply chain. PBMs as the core source of price inflation (Priority: 5/5): He argues that pharmacy benefit managers function like a cartel, capturing 30-40% of drug spending and creating massive price discrepancies between list price, insurance price, and true acquisition cost. Founder origin story and company formation (Priority: 4/5): The company began as a nonprofit, failed to raise funding, then pivoted to a public benefit corporation after advice from Sam Altman and later gained traction through a cold email to Mark Cuban. Manufacturing and vertical integration (Priority: 4/5): Cost Plus Drugs expanded into manufacturing to address drug shortages and neglected products, using robotics and sterile automated systems to scale production efficiently. Growth driven by word of mouth and customer demand (Priority: 4/5): The business grew without paid marketing; social media and patient communities created viral demand once cheaper drugs were discovered. Technology, AI, and operational scaling (Priority: 3/5): Automation, robotic manufacturing, and AI are framed as tools to improve speed, flexibility, and global scalability rather than just cost reduction. Policy skepticism and private-sector reform (Priority: 3/5): Oshmiansky is skeptical that legislation alone will fix the problem, arguing that large employers and private-sector buyers can pressure the system into reform.

Key Arguments: Drug pricing is distorted less by manufacturers alone than by PBMs that sit in the middle and extract large rents. Transparency in pricing can reveal that many drugs are far cheaper than patients are told, sometimes by orders of magnitude. A small, mission-driven company can outperform entrenched incumbents by bypassing opaque intermediaries and simplifying distribution. Word-of-mouth among patient communities is a powerful growth engine when the product delivers dramatic savings. Manufacturing is necessary for certain neglected or shortage drugs because the market will not reliably supply them. Automation and robotics are not only about lowering cost but about keeping pace with demand and improving fulfillment speed. Private-sector purchasing decisions by large employers may be more effective than slow-moving policy reform. The company’s model can help both patients and manufacturers because manufacturers often earn more through a transparent direct channel than through PBM-controlled distribution.

Data Points: Pricing model margin: 15% margin plus fixed fees - Cost Plus Drugs’ core structure for drug pricing includes a 15% margin, $5 pharmacist fee, and $5 shipping/handling. Pharmacist fee: $5 - Fixed fee included in the company’s pricing breakdown. Shipping and handling: $5 - Fixed shipping/handling fee in the final consumer price. PBM share of drug spending: 30-40% - Estimated portion of all drug spending captured by pharmacy benefit managers. Example insurance out-of-pocket cost: $3,000-$4,000 - High-deductible patients may be asked to pay this much for drugs that Cost Plus sells for tens of dollars. Example direct drug cost: $20-$30 per month - Price for certain drugs on Cost Plus Drugs compared with far higher insured or list prices. Example list price: $10,000 per month - A cited manufacturer/list price used by PBMs to justify a supposedly large discount. Example insulin price: $20 per vial - Approximate price big pharma was selling insulin for, according to Oshmiansky’s comments. Insulin list price: $400 per vial - Cited list price that could leave patients unable to afford insulin. Bosentan price example: $10,000 per month - Generic bosentan still cost this much for patients despite being long off patent. Albendazole example: $250 per tablet vs about $5 - Cost Plus initially sourced the drug far below the market price. Launch timing: January 2022 - Direct-to-consumer mail-order business launched then and quickly scaled. Growth rate: 20-30% month over month - A period in late 2022 when the company was struggling to keep up with demand. Fulfillment speed: 1.5 days average - Current average time for prescriptions to go out. Potential production switch time: within 4 hours - Robot-based manufacturing systems can pivot between products quickly in principle. Children lacking chemotherapy globally: 120,000 per year - Estimate cited from the International Society of Pediatric Oncology. Seed round: a little over $1 million - Funding raised after converting from nonprofit to public benefit corporation. Company trajectory estimate: 3% along the journey - Oshmiansky says Cost Plus is still early in its mission.

Pivotal Quotes: "We use vertical integration for good instead of evil." — Alex Oshmiansky: Describing the company’s strategy of combining manufacturing, distribution, and supply-chain control to fix drug pricing and shortages. "They need you more than you need them." — Alex Oshmiansky: His pitch to pharmaceutical companies that feared retaliation from PBMs and avoided working with Cost Plus Drugs. "The essence of medicine is the assumption of responsibility." — Alex Oshmiansky: Explaining how his weekly radiology work reinforces discipline and decision-making in founding the company.

Implications: The episode suggests healthcare disruption can come from transparency, direct purchasing, and patient-led demand rather than policy alone. It also signals that robotics, AI, and vertical integration may reshape drug access, shortage response, and pricing norms.